Cti Biopharm $CTI stock continues in a strong uptrend and has now picked up coverage from Cowen.
Cowen starts CTI BioPharma at Outperform
On July 7, 2022, Cowen analyst Boris Peaker initiated coverage of CTI BioPharma with an Outperform rating and $10 price target. CTI is commercializing a JAK2/IRAK1 inhibitor for thrombocytopenic myelofibrosis which was approved in February, Peaker tells investors in a research note. The analyst’s physician survey suggests “strong adoption on the label and “significant potential upside” in patients with platelets of 50-100, which is off-label. He sees a “high growth opportunity” in the established indication.
📺 FDA approves CTI BioPharma’s (CTIC) bone marrow cancer drug! 🚀🌙
$CTI stock is in a strong uptrend and is trying to break out above its previous consolidation resistance high.